Maria Jose Blanco Prieto

Maria J. Blanco Prieto is a Full Professor of Pharmacy and Pharmaceutical Technology at the University of Navarra (UNAV).  She is the author of more than 135 research papers and book chapters with more than 4.100 cites (H-index 41), 4 editorials, 5 patents and has over 170 communications at scientific conferences, many of them as invited speaker. She is/was responsible of more than 25 competitive research projects and she is expert for the European Commission for nanomedicines. Her  research in drug delivery has won her numerous awards.

Annalisa Delnevo

With a Master degree in Theoretical Physics at Modena Reggio Emilia University, Annalisa Delnevo started his brilliant career in 1994 and she worked for more than fourteen years in Biomedical Companies.
During this period, thanks to her capabilities and resourcefulness developed over the years she gained more and more responsibilities in R&D, New Product Development, Innovation and Science. For coming five years she had experiences in different business areas always in technical areas.
She then took important challenges as temporary manager in multiple situations.
She entered in Stevanato Group in 2016 as SG Lab Advanced Technology Manager where she could take advantage of the skills and knowledge acquired in the previous working experiences to contribute to the improvement of the function.
Since April 2017, she is responsible for the Research Department of the Pharmaceutical Systems Division of Stevanato Group with cross functional responsibilities and a crucial role for the growth of the company.

Stefaan De Smedt

Stefaan De Smedt studied pharmacy at Ghent University. Following his doctoral studies he joined Janssen Pharmaceutica. He did post-doctoral research in Ghent and Utrecht and became Professor in Physical Pharmacy and Biopharmacy at Ghent University (1999) where he founded the Ghent Research Group on Nanomedicines. He served as dean of his faculty between 2010 and 2014. Since 2014 he is a member of the Board of Directors of Ghent University. Stefaan De Smedt’ s research is at the interface between drug delivery, biophysics, material sciences and physical chemistry. He has strongly enjoyed to be the scientific promoter and mentor of +45 doctoral students. Since 2004  he serves as Editor of the Journal of Controlled Release. He is a Distinguished Visiting Scientist of the Chinese Academy of Sciences and member of the Belgian Royal Academy of Medicine. Recently he has been elected as a member of the European Academy of Sciences.

Giustino Di Pretoro

Giustino Di Pretoro, PhD, is an Associate Director at Janssen Pharmaceutica, a Johnson & Johnson Company. Dr. Di Pretoro is a subject matter expert and drug product development lead for continuous manufacturing, and coordinator for a series of academic collaborations within the field.

Before joining Johnson & Johnson, Giustino was Team Leader and Principal Scientist at Novo Nordisk AS (DK), where he was heading a formulation team focusing on oral delivery of biomolecules, and prior as R&D and Business Development Manager for a Swiss CMO, focussing on novel technologies for particle size reduction and solubility improvement of class II BCS drugs.

Giustino holds a Ph.D. in Pharmaceutical Technology and Msc. in Industrial Pharmacy, from the University of Milan (I). Within his Ph.D. he worked as Research Scientist at the University of Cambridge (UK) in the Chemical Engineering and Biotechnology department, and later as visiting postdoc in Pharmaceutical Technology at the University of Düsseldorf (DE).

Paolo Gatti

Dr. Paolo Gatti graduated with honours in Pharmaceutical Chemistry at the University of Genoa in 1994 and defended his PhD thesis in Pharmaceutical Sciences in 1999. In the same year he started his career in pharmaceutical industry covering in the following twenty years positions of increasing responsibility in R&D of Pharmacia&Upjhon, Pfizer, Eurand, BSP Pharmaceuticals and Evotec where currently he has the role of Senior Scientific Director.

Among his career achievements, the contribution as pharmaceutical development team leader to successful registration in USA, Europe and Japan of Pfizer’s new anticancer drug sunitinib maleate.

Dr Gatti background and research interests include development of formulations to speed-up new chemical entity clinical studies; bioavailability improvement of poorly soluble drugs; patient-centric dosage from development, oral solid and freeze dried dosage forms process development and scale-up.

He is faculty member of Master Courses at universities of Pavia and Siena and is invited lecturer in other universities and professional advancement courses. He is author of peer reviewed papers and patents and is the co-author of a book on Pharmaceutical Industry Equipments and Processes.

Alice Melocchi

After graduating cum laude in Pharmacy, Alice Melocchi, PhD, spent 9 months at Massachusetts Institute of Technology as a visiting student and, in 2015, earned her Ph.D. from Università degli Studi di Milano Currently, she is a post-doc at the Department of Pharmaceutical Sciences of the same university.

Her research activity concerns the exploitation of hot melt extrusion, injection molding and fused deposition modeling as advantageous alternatives for the production of already existing dosage forms or for the manufacturing of innovative drug delivery systems. Starting from 2016, Alice is also the CTO of Multiply Labs, a startup selected in Y Combinator and focused on 3D printing of capsules for controlled release of personalized supplements.

Paola Minghetti

Paola Minghetti, graduate in Pharmacy and Industrial Pharmacy, PhD in Pharmaceutical Sciences, is full professor of Pharmaceutical Technology and Legislation at Università degli Studi di Milano. 

She is an expert of the Italian Pharmacopoeia and  member of a team appointed by EDQM for the creation of the monograph “Pharmaceutical Dosage Forms”. She is member of the AIFA evaluation and authorization Secretariat since 2012. Her main research field is related to transdermal and buccal drug delivery systems. and to the doctrinal elaboration regards the national and UE legislation related to the production and the commercialization of medicaments, medical devices, and health products.

Julien Nicolas

Julien Nicolas completed his Ph.D. in 2005 at the University Pierre and Marie Curie in Paris (France), where he studied nitroxide-mediated polymerization. He then did a post-doc at Warwick University (U.K.) in the field of polymer–protein bioconjugates. In 2007, he obtained a CNRS researcher position at Institut Galien Paris-Sud (Univ. Paris-Sud) in Châtenay-Malabry (France) and was promoted to CNRS Research Director in 2016. His current research activities lie in advanced macromolecular synthesis and in the design of polymer-based nanomedicines, especially polymer nanoparticles and polymer prodrug nanocarriers. He is (co)author of more than 90 peer review articles in international journals, 8 patents, and 14 book chapters. In 2016, he was appointed Associate Editor of Chemistry of Materials (ACS). He won the French Polymer Society (GFP) / French Chemical Society (SCF) award in 2016, the Polymer Chemistry Lectureship award in 2017 and the "Prix Novacap de l’Académie des Sciences" in 2018. 

Odra Pinato

Odra Pinato is the Manager of SG Lab Analytics, a is Stevanato Group’s advanced laboratory focused on analytical chemistry, material properties, physical and mechanical performances testing on pharmaceutical packaging. Odra Pinato is a pharmaceutical biotechnologist with a PhD in Biochemistry and Biotechnology. Her academic background is focused on protein chemistry with a 2-year post-doctoral experience in pharmaceutical biophysics. She has also expertise on the development and validation of chromatographic methods and stability studies for the quality assessment of drug products and on physical and chemical characterization of proteins for biopharmaceutical purposes.

Marc Schiller

Dr. rer nat Marc Schiller studied from 1993 to 1997 pharmacy at Eberhard-Karls University Tübingen and in December 1998 he absolved his approbation as pharmacist.From 1999 to 2002 he made his conferral of a doctorate in Pharmaceutical Technology at Eberhard-Karls University Tübingen Title of the work “Analytical and technological optimization on film coated tablets containing herbal dry extracts of Eschscholtzia californica Cham.”. 

Has was head of Laboratory in Pharmaceutical Development of ALTANA Pharma, Konstanz from 2002 to 2007 and from 2004 - 2018 head of Production (Herstellungsleiter/Leiter der Herstellung according to German drug law) for clinical supply bulk manufacturing and from January – September 2007 he was Group leader with 5 direct reports and 12 reports in Pharmaceutical Development of ALTANA Pharma (member of Nycomed group), Konstanz. October 2007 to January 2012 he worked as Group Leader NCE Formulation (with 3 direct reports and 10 reports) in Pharmaceutical Development of Grünenthal GmbH, Aachen. February 2012 to June 2014 he assumend the function as head of Pharmaceutical Development NCEs (4 direct reports and 12 reports)in Pharmaceutical Development of Grünenthal GmbH, Aachen. Since July 2014 he is head of Pharmaceutical Development (up to 6 direct reports and 26 reports) of Grünenthal GmbH, Aachen.

Guy Van den Mooter

Guy Van den Mooter (°1964) obtained his Ph.D. in 1994 (university of Leuven - KU Leuven, pharmaceutical technology). Following a position as scientist at Janssen Research Foundation (Beerse, Belgium), he obtained a post-doctoral position at the laboratory of Pharmacotechnology and Biopharmacy at the university of Leuven. In 1999 he was appointed as assistant-professor, and since 2009 he is full professor at the faculty of Pharmaceutical Sciences in the Drug Delivery and Disposition research group.  

The focus of his research group is the formulation, process development and physical chemistry of drug-polymer solid dispersions, nanocrystals and mesoporous silica drug delivery systems. The main objective is to explore the relationship between the formulation, the process applied and the performance in terms of stability and drug release. His research requires the use of processing technologies such as spray drying, hot melt extrusion, fluid bed coating, cryo-grinding, electrospraying,  and analytical techniques such as (modulated) differential scanning calorimetry, X-ray powder diffraction, infrared spectroscopy, laser diffraction, dynamic light scattering, NMR (solution and solid state), and drug release testing. 

He has published over 240 scientific papers in international peer-reviewed journals (H-index = 50, > 7700 citations). 

In 2007, he co-founded the spin-off company Formac Pharmaceuticals. 

He teaches courses of pharmaceutical technology, preformulation and physical chemistry in undergraduate and graduate programs. He is coordinator of the master program in industrial pharmacy. He is member of the Belgian Pharmacopeia commission and member of the editorial board of several scientific journals. 

Werner Weitschies

Werner Weitschies is Professor of Biopharmaceutics at the University of Greifswald, Germany. He studied Pharmacy at the Free University of Berlin (1983-1987) and received his Ph.D. in Pharmaceutical Technology in 1990. From 1990 to 1995 he worked as a scientist in the research laboratories of Schering AG in Berlin in the field of injectable microparticulate contrast agents for ultrasound. From 1996 to 1998 he was head of a research department in the field of medical applications of magnetic nanoparticles at the Institute for Diagnostic Research of the Free University of Berlin. In 1998 he was appointed Professor of Pharmaceutical Technology at the Institute of Pharmacy in Greifswald, Germany. His main research areas are the investigation of the interplay between physiology and drug delivery systems with focus on the gastrointestinal tract. Werner Weitschies is author or co-author of more than 250 scientific articles and 30 patents.

Iris Ziegler

Dr. Iris M. Ziegler obtained her PhD in 1996 from the Ludwig-Maximilians-Universität in Munich. 

She worked in the pharmaceutical development at Grünenthal, as Director of Pharmaceutical Development at Nycomed and at Corden Pharma Plankstadt, a specialist CDMO for highly potent drug products, as Director Development and Production and a board member of the site. 

Since 2017 Iris Ziegler has been Director of Pharmaceutical Sciences and QbD at Corden Pharma International.

She strongly supports the concept of a systematic, science driven development, employing risk based decisions and mitigation concepts and has always promoted the roll out of a QbD driven development.

She has given numerous presentations on oral solid dosage form topics, and about working in containment areas and why a QbD driven development is especially important there.

She has published several papers and is the inventor and co-inventor of several patents. 

Since 2006 she has been a member of the APV’s Focus Group “Solid Dosage Forms” now being its leader. She is also in the core team of the Manufacturing Classification System initiative.